Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Research



Study on oral anti-diabetic drug utilization pattern in diabetes mellitus type 2 patients at a tertiary care hospital

Inugurthy Sridhar, Polagani Padma, MD. Zubair Ahmed, Syeda Ayesha Siddiqua.

Abstract
Background: Diabetes mellitus (DM) type 2, the chief public health issue all over the globe affecting mostly developing countries. The prescribed oral anti-diabetic drugs play a key role in the treatment and management of DM type 2. Drug utilization study of oral anti-diabetic drugs is of extreme prominence to promote rational usage of the drug in DM type 2 patients and to spread knowledge and understanding for the oral anti-diabetic medicines prescribed.

Aim and Objectives: Our study aims to determine the oral anti-diabetic drug utilization pattern in DM type 2 patients at a tertiary care hospital.

Materials and Methods: A prospective, cross-sectional, and observational study of 6 months period was conducted among DM type 2 patients attending the General Medicine department of a tertiary care hospital. One hundred and fifty-seven DM type 2 patients participated and their prescriptions were screened. Ethics committee permission was obtained from the institutional ethical committee before initiation of the study. Required demographic details, body mass index (BMI), duration, and family history of DM type 2 were noted. Five classes of oral anti-diabetic drugs: Biguanides, Sulfonylureas, Alpha-Glucosidase inhibitors, Dipeptidyl Peptidase-4 inhibitors, and Thiazolidinediones were analyzed in the study.

Results: One hundred and fifty-seven DM type 2 patients participated in the study. The majority of the patients were from the age group of 4150 years (45.9%) and female predominance was observed (59.2%). BMI calculations showed most of them were belonging to the obese category (45.2%). 610 years of the duration period of DM type 2 (34.4%) among the participants were the highest. About 58% had a strong family history of DM type 2. Among the oral anti-diabetic drugs prescribed metformin (Biguanides) was found to be a commonly prescribed drug (26.1%), followed by glimepiride (Sulfonylureas) (21.0%). Among the reported adverse effects hypoglycemia (7%) was the most prevalent one.

Conclusion: The study showed that metformin, that is, Biguanides are the predominantly utilized oral anti-diabetic drugs followed by glimepiride, that is, Sulfonylureas in DM type 2 patients.

Key words: Oral Anti-diabetic Drugs; Drug Utilization Pattern; Diabetes Mellitus Type 2; Adverse Effects



Similar Articles

Current Concepts in Prophylactic Antibiotics in Oral and Maxillofacial Surgery.
Dammling C, Abramowicz S, Kinard B
Oral and maxillofacial surgery clinics of North America. 2022; 34(1): 157-167

Exosome treatment for stroke with diabetic comorbidity.
Venkat P, Chopp M
Neural regeneration research. 2022; 17(2): 315-317

In vitro and in silico anti-osteoporosis activities and underlying mechanisms of a fructan, ABW90-1, from Achyranthes bidentate.
Li T, Hou X, Huang Y, Wang C, Chen H, Yan C
Carbohydrate polymers. 2022; 276(): 118730

Drug-drug interaction between cannabidiol and phenobarbital in healthy dogs.
Doran CE, McGrath S, Bartner LR, Thomas B, Cribb AE, Gustafson DL
American journal of veterinary research. 2022; (): 1-9

Artificial Intelligence and Quantum Computing as the Next Pharma Disruptors.
Cova T, Vitorino C, Ferreira M, Nunes S, Rondon-Villarreal P, Pais A
Methods in molecular biology (Clifton, N.J.). 2022; 2390(): 321-347


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites